|
|
Volumn 168, Issue 3, 2013, Pages 1721-1723
|
|
Refuting the ticagrelor-aspirin black box warning: And proposing a ticagrelor early-PCI black box warning
a
|
|
Author keywords
Clinical Trials; Clopidogrel; Percutaneous Coronary Interventions; Ticagrelor
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
CLOPIDOGREL;
FIBRINOGEN RECEPTOR ANTAGONIST;
PURINERGIC P2Y12 RECEPTOR;
TICAGRELOR;
BARE METAL STENT;
BLACK BOX WARNING;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR MORTALITY;
CORONARY ARTERY BYPASS GRAFT;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG ELUTING STENT;
DRUG HALF LIFE;
DRUG MEGADOSE;
DRUG PACKAGING;
DRUG USE;
DRUG WITHDRAWAL;
EARLY INTERVENTION;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LOADING DRUG DOSE;
LOW DRUG DOSE;
MAINTENANCE THERAPY;
PERCUTANEOUS CORONARY INTERVENTION;
PREVALENCE;
PRIORITY JOURNAL;
REVIEW;
CLINICAL TRIALS;
CLOPIDOGREL;
PERCUTANEOUS CORONARY INTERVENTIONS;
TICAGRELOR;
ACUTE CORONARY SYNDROME;
ADENOSINE;
ASPIRIN;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG THERAPY, COMBINATION;
HUMANS;
PERCUTANEOUS CORONARY INTERVENTION;
PLATELET AGGREGATION INHIBITORS;
PURINERGIC P2Y RECEPTOR ANTAGONISTS;
TIME FACTORS;
|
|
EID: 84885623587
PISSN: 01675273
EISSN: 18741754
Source Type: Journal
DOI: 10.1016/j.ijcard.2013.05.060 Document Type: Editorial |
|
Times cited : (5)
|
|
References (6)
|
